Abiraterone
The metabolism of Dexlansoprazole can be decreased when combined with Abiraterone.
Alendronate
The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Dexlansoprazole.
Alendronic acid
The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Dexlansoprazole.
Advertisement
Amiodarone
The metabolism of Dexlansoprazole can be decreased when combined with Amiodarone.
Amphetamine
Dexlansoprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Anhydrous Tacrolimus
The serum concentration of Tacrolimus can be increased when it is combined with Dexlansoprazole.
Advertisement
Apalutamide
The serum concentration of Dexlansoprazole can be decreased when it is combined with Apalutamide.
Aprepitant
The serum concentration of Dexlansoprazole can be increased when it is combined with Aprepitant.
Armodafinil
The metabolism of Dexlansoprazole can be decreased when combined with Armodafinil.
Advertisement
Atazanavir
Dexlansoprazole can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Atomoxetine
The metabolism of Dexlansoprazole can be decreased when combined with Atomoxetine.
Boceprevir
The metabolism of Dexlansoprazole can be decreased when combined with Boceprevir.
Bortezomib
The metabolism of Dexlansoprazole can be decreased when combined with Bortezomib.
Bosentan
The serum concentration of Dexlansoprazole can be decreased when it is combined with Bosentan.
Bosutinib
The serum concentration of Bosutinib can be decreased when it is combined with Dexlansoprazole.
Bosutinib monohydrate
The serum concentration of Bosutinib can be decreased when it is combined with Dexlansoprazole.
Carbamazepine
The metabolism of Dexlansoprazole can be increased when combined with Carbamazepine.
Cefditoren
The serum concentration of Cefditoren can be decreased when it is combined with Dexlansoprazole.
Ceritinib
The serum concentration of Dexlansoprazole can be increased when it is combined with Ceritinib.
Chloramphenicol
The metabolism of Dexlansoprazole can be decreased when combined with Chloramphenicol.
Cholecalciferol
The metabolism of Dexlansoprazole can be decreased when combined with Cholecalciferol.
Cilostazol
The serum concentration of Cilostazol can be increased when it is combined with Dexlansoprazole.
Cimetidine
The metabolism of Dexlansoprazole can be decreased when combined with Cimetidine.
Citalopram
The metabolism of Dexlansoprazole can be decreased when combined with Citalopram.
Clarithromycin
The metabolism of Dexlansoprazole can be decreased when combined with Clarithromycin.
Clemastine
The metabolism of Dexlansoprazole can be decreased when combined with Clemastine.
Clodronic Acid
The therapeutic efficacy of Clodronic Acid can be decreased when used in combination with Dexlansoprazole.
Clopidogrel
The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Dexlansoprazole resulting in a loss in efficacy.
Clotrimazole
The metabolism of Dexlansoprazole can be decreased when combined with Clotrimazole.
Cobicistat
The metabolism of Dexlansoprazole can be decreased when combined with Cobicistat.
Conivaptan
The serum concentration of Conivaptan can be increased when it is combined with Dexlansoprazole.
Crizotinib
The metabolism of Dexlansoprazole can be decreased when combined with Crizotinib.
Cyclosporine
The metabolism of Dexlansoprazole can be decreased when combined with Cyclosporine.
Cysteamine
The therapeutic efficacy of Cysteamine can be decreased when used in combination with Dexlansoprazole.
Dabigatran Etexilate
The serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with Dexlansoprazole resulting in a loss in efficacy.
Dabrafenib
The serum concentration of Dabrafenib can be decreased when it is combined with Dexlansoprazole.
Darunavir
The metabolism of Dexlansoprazole can be decreased when combined with Darunavir.
Dasatinib
The serum concentration of Dasatinib can be decreased when it is combined with Dexlansoprazole.
Dasatinib Anhydrous
The serum concentration of Dasatinib can be decreased when it is combined with Dexlansoprazole.
Deferasirox
The serum concentration of Dexlansoprazole can be decreased when it is combined with Deferasirox.
Delavirdine
The serum concentration of Delavirdine can be decreased when it is combined with Dexlansoprazole.
Dexmethylphenidate
Dexlansoprazole can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Dextroamphetamine
Dexlansoprazole can cause an increase in the absorption of Dextroamphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Dihydroergotamine
The metabolism of Dexlansoprazole can be decreased when combined with Dihydroergotamine.
Diltiazem
The metabolism of Dexlansoprazole can be decreased when combined with Diltiazem.
Doxycycline
The metabolism of Dexlansoprazole can be decreased when combined with Doxycycline.
Doxycycline Anhydrous
The metabolism of Dexlansoprazole can be decreased when combined with Doxycycline.
Dronedarone
The metabolism of Dexlansoprazole can be decreased when combined with Dronedarone.
Efavirenz
The metabolism of Dexlansoprazole can be decreased when combined with Efavirenz.
Enzalutamide
The serum concentration of Dexlansoprazole can be decreased when it is combined with Enzalutamide.
Erlotinib
The serum concentration of Erlotinib can be decreased when it is combined with Dexlansoprazole.
Erythromycin
The metabolism of Dexlansoprazole can be decreased when combined with Erythromycin.
Eslicarbazepine Acetate
The metabolism of Dexlansoprazole can be decreased when combined with Eslicarbazepine acetate.
Esomeprazole
The metabolism of Dexlansoprazole can be decreased when combined with Esomeprazole.
Etidronate
The therapeutic efficacy of Etidronic acid can be decreased when used in combination with Dexlansoprazole.
Etidronic Acid
The therapeutic efficacy of Etidronic acid can be decreased when used in combination with Dexlansoprazole.
Etravirine
The metabolism of Dexlansoprazole can be decreased when combined with Etravirine.
Ferric Carboxymaltose
Dexlansoprazole can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric Pyrophosphate
Dexlansoprazole can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Fluconazole
The serum concentration of Dexlansoprazole can be increased when it is combined with Fluconazole.
Fluoxetine
The metabolism of Dexlansoprazole can be decreased when combined with Fluoxetine.
Fluvoxamine
The metabolism of Dexlansoprazole can be decreased when combined with Fluvoxamine.
Fosamprenavir
The metabolism of Dexlansoprazole can be decreased when combined with Fosamprenavir.
Fosaprepitant
The serum concentration of Dexlansoprazole can be increased when it is combined with Fosaprepitant.
Fosphenytoin
The metabolism of Dexlansoprazole can be increased when combined with Fosphenytoin.
Fusidate
The serum concentration of Dexlansoprazole can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Dexlansoprazole can be increased when it is combined with Fusidic Acid.
Gefitinib
The serum concentration of Gefitinib can be decreased when it is combined with Dexlansoprazole.
Gemfibrozil
The metabolism of Dexlansoprazole can be decreased when combined with Gemfibrozil.
Hypoxis hemerocallidea root extract
The serum concentration of Dexlansoprazole can be decreased when it is combined with St. John's Wort.
Ibandronate
The therapeutic efficacy of Ibandronate can be decreased when used in combination with Dexlansoprazole.
Ibandronic Acid
The therapeutic efficacy of Ibandronate can be decreased when used in combination with Dexlansoprazole.
Idelalisib
The metabolism of Dexlansoprazole can be decreased when combined with Idelalisib.
Imatinib
The metabolism of Dexlansoprazole can be decreased when combined with Imatinib.
Indinavir
The serum concentration of Indinavir can be decreased when it is combined with Dexlansoprazole.
INDINAVIR ANHYDROUS
The serum concentration of Indinavir can be decreased when it is combined with Dexlansoprazole.
Iron
Dexlansoprazole can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iron Carbonyl
Dexlansoprazole can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iron Sucrose
Dexlansoprazole can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iron-Dextran Complex
Dexlansoprazole can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
Isavuconazole
The serum concentration of Dexlansoprazole can be increased when it is combined with Isavuconazole.
Isavuconazonium
The metabolism of Dexlansoprazole can be decreased when combined with Isavuconazonium.
Isoniazid
The metabolism of Dexlansoprazole can be decreased when combined with Isoniazid.
Isradipine
The metabolism of Dexlansoprazole can be decreased when combined with Isradipine.
Itraconazole
The serum concentration of Itraconazole can be decreased when it is combined with Dexlansoprazole.
Ivacaftor
The serum concentration of Dexlansoprazole can be increased when it is combined with Ivacaftor.
Ketoconazole
The serum concentration of Ketoconazole can be decreased when it is combined with Dexlansoprazole.
Ledipasvir
The serum concentration of Ledipasvir can be decreased when it is combined with Dexlansoprazole.
Lopinavir
The metabolism of Dexlansoprazole can be decreased when combined with Lopinavir.
Lovastatin
The metabolism of Dexlansoprazole can be decreased when combined with Lovastatin.
Luliconazole
The serum concentration of Dexlansoprazole can be increased when it is combined with Luliconazole.
Lumacaftor
The serum concentration of Dexlansoprazole can be decreased when it is combined with Lumacaftor.
Medronate
The therapeutic efficacy of Technetium Tc-99m medronate can be decreased when used in combination with Dexlansoprazole.
Mesalamine
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Dexlansoprazole.
Methotrexate
The serum concentration of Methotrexate can be increased when it is combined with Dexlansoprazole.
Methylphenidate
Dexlansoprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Mifepristone
The serum concentration of Dexlansoprazole can be increased when it is combined with Mifepristone.
Mitotane
The serum concentration of Dexlansoprazole can be decreased when it is combined with Mitotane.
Moclobemide
The metabolism of Dexlansoprazole can be decreased when combined with Moclobemide.
Modafinil
The metabolism of Dexlansoprazole can be decreased when combined with Modafinil.
MYCOPHENOLATE
The serum concentration of Mycophenolic acid can be decreased when it is combined with Dexlansoprazole.
Mycophenolic Acid
The serum concentration of Mycophenolic acid can be decreased when it is combined with Dexlansoprazole.
Nefazodone
The metabolism of Dexlansoprazole can be decreased when combined with Nefazodone.
Nelfinavir
The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Dexlansoprazole resulting in a loss in efficacy.
Netupitant
The serum concentration of Dexlansoprazole can be increased when it is combined with Netupitant.
Nevirapine
The metabolism of Dexlansoprazole can be increased when combined with Nevirapine.
Nicardipine
The metabolism of Dexlansoprazole can be decreased when combined with Nicardipine.
Nilotinib
The serum concentration of Nilotinib can be decreased when it is combined with Dexlansoprazole.
Olaparib
The metabolism of Dexlansoprazole can be decreased when combined with Olaparib.
Omeprazole
The metabolism of Dexlansoprazole can be decreased when combined with Omeprazole.
Osimertinib
The serum concentration of Dexlansoprazole can be increased when it is combined with Osimertinib.
Palbociclib
The serum concentration of Dexlansoprazole can be increased when it is combined with Palbociclib.
Pamidronate
The therapeutic efficacy of Pamidronate can be decreased when used in combination with Dexlansoprazole.
Pamidronic Acid
The therapeutic efficacy of Pamidronate can be decreased when used in combination with Dexlansoprazole.
Pantoprazole
The metabolism of Dexlansoprazole can be decreased when combined with Pantoprazole.
Pazopanib
The serum concentration of Pazopanib can be decreased when it is combined with Dexlansoprazole.
Pentobarbital
The metabolism of Dexlansoprazole can be increased when combined with Pentobarbital.
Phenobarbital
The metabolism of Dexlansoprazole can be increased when combined with Phenobarbital.
Phenytoin
The metabolism of Dexlansoprazole can be increased when combined with Phenytoin.
Posaconazole
The serum concentration of Posaconazole can be decreased when it is combined with Dexlansoprazole.
Primidone
The metabolism of Dexlansoprazole can be increased when combined with Primidone.
Raltegravir
The serum concentration of Raltegravir can be increased when it is combined with Dexlansoprazole.
Ranolazine
The metabolism of Dexlansoprazole can be decreased when combined with Ranolazine.
Rifabutin
The metabolism of Dexlansoprazole can be increased when combined with Rifabutin.
Rifampin
The metabolism of Dexlansoprazole can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Dexlansoprazole can be increased when combined with Rifapentine.
Riociguat
The serum concentration of Riociguat can be decreased when it is combined with Dexlansoprazole.
Risedronate
The therapeutic efficacy of Risedronate can be decreased when used in combination with Dexlansoprazole.
Risedronic Acid
The therapeutic efficacy of Risedronate can be decreased when used in combination with Dexlansoprazole.
Rucaparib
The metabolism of Dexlansoprazole can be decreased when combined with Rucaparib.
Saquinavir
The serum concentration of Saquinavir can be increased when it is combined with Dexlansoprazole.
Saquinavir Mesylate
The serum concentration of Saquinavir can be increased when it is combined with Dexlansoprazole.
Sarilumab
The therapeutic efficacy of Dexlansoprazole can be decreased when used in combination with Sarilumab.
Sertraline
The metabolism of Dexlansoprazole can be decreased when combined with Sertraline.
Sildenafil
The metabolism of Dexlansoprazole can be decreased when combined with Sildenafil.
Siltuximab
The serum concentration of Dexlansoprazole can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Dexlansoprazole can be increased when it is combined with Simeprevir.
ST. JOHN'S WORT EXTRACT
The serum concentration of Dexlansoprazole can be decreased when it is combined with St. John's Wort.
Sucroferric Oxyhydroxide
Dexlansoprazole can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sulfisoxazole
The metabolism of Dexlansoprazole can be decreased when combined with Sulfisoxazole.
Tacrolimus
The serum concentration of Tacrolimus can be increased when it is combined with Dexlansoprazole.
Technetium Tc 99m Medronate
The therapeutic efficacy of Technetium Tc-99m medronate can be decreased when used in combination with Dexlansoprazole.
Telaprevir
The metabolism of Dexlansoprazole can be decreased when combined with Telaprevir.
Telithromycin
The metabolism of Dexlansoprazole can be decreased when combined with Telithromycin.
Ticlopidine
The metabolism of Dexlansoprazole can be decreased when combined with Ticlopidine.
Tiludronate
The therapeutic efficacy of Tiludronic acid can be decreased when used in combination with Dexlansoprazole.
Tiludronic Acid
The therapeutic efficacy of Tiludronic acid can be decreased when used in combination with Dexlansoprazole.
Tipranavir
The serum concentration of Dexlansoprazole can be decreased when it is combined with Tipranavir.
Tocilizumab
The serum concentration of Dexlansoprazole can be decreased when it is combined with Tocilizumab.
Topiramate
The metabolism of Dexlansoprazole can be decreased when combined with Topiramate.
Tranylcypromine
The metabolism of Dexlansoprazole can be decreased when combined with Tranylcypromine.
Vemurafenib
The serum concentration of Dexlansoprazole can be decreased when it is combined with Vemurafenib.
Venlafaxine
The metabolism of Dexlansoprazole can be decreased when combined with Venlafaxine.
Verapamil
The metabolism of Dexlansoprazole can be decreased when combined with Verapamil.
Voriconazole
The serum concentration of Dexlansoprazole can be increased when it is combined with Voriconazole.
Ziprasidone
The metabolism of Dexlansoprazole can be decreased when combined with Ziprasidone.
Zoledronic Acid
The therapeutic efficacy of Zoledronic acid can be decreased when used in combination with Dexlansoprazole.
Zoledronic Acid Anhydrous
The therapeutic efficacy of Zoledronic acid can be decreased when used in combination with Dexlansoprazole.
